

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

OrganOx *metra* for liver transplant ID5116

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • OrganOx (OrganOx <i>metra</i>) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addenbrookes Charitable Trust • Addenbrookes Liver Transplant Association • British Liver Trust • GUTS UK • Hepatitis C Trust • Leeds Hospitals Charity • Liver4Life • Pelican Cancer Foundation • Race equality foundation • South Asian Health Foundation • Specialised Healthcare Alliance • University Hospitals Birmingham Charity <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Surgeons of Great Britain and Ireland • Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland • British Association for the Study of the Liver • British Geriatrics Society • British Society of Gastroenterology • British Transplantation Society • NHS Blood and Transplant • Primary care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of Nursing • Royal College of Pathologists • Royal Pharmaceutical Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Association of British HealthTech Industries • Board of Community Health Councils in Wales • British in Vitro Diagnostics Association (BIVDA) • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Health Tech Alliance • Healthcare Improvement Scotland • Human Tissue Authority • Medical technology group • Medicines and Healthcare products Regulatory Agency • MedTech Europe • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • NHS Supply Chain • Scottish Medicines Consortium • Scottish Society of Gastroenterology • Edinburgh Transplant Centre, Royal Infirmary of Edinburgh • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • TransMedics (Transmedics Organ Care System) • XVIVO (Liver assist, Organ Assist)

Provisional stakeholder list for the evaluation of organOx *metra* for liver transplant ID5116

Issue date: July 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Physicians • Royal Society of Medicine • Royal College of Surgeons • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Cambridge University Hospitals NHS Foundation Trust • Department of Health and Social Care • Freeman Hospital Newcastle • Kings College Hospital London • NHS England • NHS North Central London CCG • NHS North Norfolk CCG • Queen Elizabeth Hospital, Birmingham • Royal Free Hospital • St James's University Hospital, Leeds Teaching Hospitals NHS Trust • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Cochrane UK • Foundation for Liver Research • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.